Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.

He K, Luettgen JM, Zhang D, He B, Grace JE Jr, Xin B, Pinto DJ, Wong PC, Knabb RM, Lam PY, Wexler RR, Grossman SJ.

Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):129-39. doi: 10.1007/s13318-011-0037-x. Epub 2011 Apr 2.

PMID:
21461793
[PubMed - indexed for MEDLINE]
2.

Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits.

Zhang D, He K, Raghavan N, Wang L, Crain EJ, He B, Xin B, Luettgen JM, Wong PC.

J Thromb Thrombolysis. 2010 Jan;29(1):70-80. doi: 10.1007/s11239-009-0401-8.

PMID:
19851712
[PubMed - indexed for MEDLINE]
3.

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.

Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, Luettgen JM, Knabb RM.

J Thromb Haemost. 2008 May;6(5):820-9. doi: 10.1111/j.1538-7836.2008.02939.x. Epub 2008 Feb 25.

PMID:
18315548
[PubMed - indexed for MEDLINE]
4.

Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor.

Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, Alexander JH.

J Thromb Thrombolysis. 2011 Aug;32(2):183-7. doi: 10.1007/s11239-011-0591-8.

PMID:
21516308
[PubMed - indexed for MEDLINE]
5.

Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.

Barrett YC, Wang Z, Frost C, Shenker A.

Thromb Haemost. 2010 Dec;104(6):1263-71. doi: 10.1160/TH10-05-0328. Epub 2010 Oct 26.

PMID:
20978714
[PubMed - indexed for MEDLINE]
6.

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor.

Wong PC, Pinto DJ, Zhang D.

J Thromb Thrombolysis. 2011 May;31(4):478-92. doi: 10.1007/s11239-011-0551-3. Review.

PMID:
21318583
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.

Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, LaCreta F.

Br J Clin Pharmacol. 2013 Feb;75(2):476-87. doi: 10.1111/j.1365-2125.2012.04369.x.

PMID:
22759198
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma.

Luettgen JM, Knabb RM, He K, Pinto DJ, Rendina AR.

J Enzyme Inhib Med Chem. 2011 Aug;26(4):514-26. doi: 10.3109/14756366.2010.535793. Epub 2010 Dec 20.

PMID:
21171894
[PubMed - indexed for MEDLINE]
9.

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.

Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ.

Drug Metab Dispos. 2010 Mar;38(3):448-58. doi: 10.1124/dmd.109.029694. Epub 2009 Nov 25. Erratum in: Drug Metab Dispos. 2010 May;38(5):887. Frost, Charles A [corrected to Frost, Charles E].

PMID:
19940026
[PubMed - indexed for MEDLINE]
Free Article
10.

A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.

Barrett YC, Wang J, Song Y, Pursley J, Wastall P, Wright R, Lacreta F, Frost C.

Thromb Haemost. 2012 May;107(5):916-24. doi: 10.1160/TH11-09-0634. Epub 2012 Mar 8.

PMID:
22398784
[PubMed - indexed for MEDLINE]
11.

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.

Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, LaCreta FP, Frost CE.

Br J Clin Pharmacol. 2013 Dec;76(6):908-16. doi: 10.1111/bcp.12114.

PMID:
23488672
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.

Kawamura M, Konishi N, Hiroe K, Shofuda K, Imaeda Y, Fujimoto T, Kubo K.

J Cardiovasc Pharmacol. 2010 Aug;56(2):156-61. doi: 10.1097/FJC.0b013e3181e2bfcf. Erratum in: J Cardiovasc Pharmacol. 2010 Oct;56(4):439.

PMID:
20410831
[PubMed - indexed for MEDLINE]
13.

Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.

Zhang D, He K, Raghavan N, Wang L, Mitroka J, Maxwell BD, Knabb RM, Frost C, Schuster A, Hao F, Gu Z, Humphreys WG, Grossman SJ.

Drug Metab Dispos. 2009 Aug;37(8):1738-48. doi: 10.1124/dmd.108.025981. Epub 2009 May 6.

PMID:
19420130
[PubMed - indexed for MEDLINE]
Free Article
14.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects.

Yamahira N, Frost C, Fukase H, Yu Z, Wang J, Pursley J, LaCreta F, Hiraoka M.

Int J Clin Pharmacol Ther. 2014 Jul;52(7):564-73. doi: 10.5414/CP201967.

PMID:
24725442
[PubMed - indexed for MEDLINE]
15.

Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa.

Graefe-Mody EU, Schühly U, Rathgen K, Stähle H, Leitner JM, Jilma B.

J Thromb Haemost. 2006 Jul;4(7):1502-9.

PMID:
16839346
[PubMed - indexed for MEDLINE]
16.

Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.

Becker RC, Alexander JH, Newby LK, Yang H, Barrett Y, Mohan P, Wang J, Harrington RA, Wallentin LC.

Thromb Haemost. 2010 Nov;104(5):976-83. doi: 10.1160/TH10-04-0247. Epub 2010 Aug 30.

PMID:
20806117
[PubMed - indexed for MEDLINE]
17.

Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.

Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, Yu Z, Shenker A, Barrett YC, Mosqueda-Garcia R, Lacreta F.

Br J Clin Pharmacol. 2013 Nov;76(5):776-86. doi: 10.1111/bcp.12106.

PMID:
23451769
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.

Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M.

Int J Clin Pharmacol Ther. 2007 Jun;45(6):335-44.

PMID:
17595891
[PubMed - indexed for MEDLINE]
19.

Tissue distribution and elimination of [14C]apixaban in rats.

Wang L, He K, Maxwell B, Grossman SJ, Tremaine LM, Humphreys WG, Zhang D.

Drug Metab Dispos. 2011 Feb;39(2):256-64. doi: 10.1124/dmd.110.036442. Epub 2010 Nov 11.

PMID:
21071521
[PubMed - indexed for MEDLINE]
Free Article
20.

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.

Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY.

J Med Chem. 2007 Nov 1;50(22):5339-56. Epub 2007 Oct 3.

PMID:
17914785
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk